ReviewCureus2025
The Role of Sulopenem in the Treatment of Uncomplicated Urinary Tract Infections: A Systematic Review and Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uncomplicated urinary tract infections (uUTIs) rank as one of the most frequent bacterial infections, particularly in females, and antimicrobial resistance is complicating the situation more and more. So, first-line agents such as nitrofurantoin and trimethoprim-sulfamethoxazole are losing their beneficial effects. There is an urgent call for new therapies due to the very alarming global rise of extended-spectrum β-lactamase-producing bacterial isolates. Sulopenem is a new antibiotic of the penem series available for both intravenous and oral administration, a potential candidate against multidrug-resistant Gram-negative organisms. It offers anti-β-lactamase stability, oral activity, and possible hospitalization duration reduction, hence, making it the best option for consideration. This article conducts a review of the evidence surrounding sulopenem regarding efficacy, safety, and resistance mechanisms. According to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, clinical trials were searched in databases, including PubMed, Scopus, Embase, Medline, and the Cochrane Library. Five studies were selected that include randomized trials, comparative effectiveness research, and pharmacokinetic/pharmacodynamic (PK/PD) modeling studies. Main outcomes were microbiological cure, resolution of symptoms, recurrence of clinical symptoms, and adverse events. Sulopenem was either non-inferior or superior to comparators in important subgroups. Ciprofloxacin-resistant infections showed better test-of-cure results with sulopenem, 62.6% versus 35.0%. Sulopenem/probenecid was equal or superior to amoxicillin/clavulanate, including among resistant strains. PK/PD modeling confirmed bactericidal concentrations for a sustained duration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.